Cargando…
Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case–control study in the CPRD
SUMMARY: We explored the cardiac safety of the osteoporosis treatment strontium ranelate in the UK Clinical Practice Research Datalink. While known cardiovascular risk factors like obesity and smoking were associated with increased cardiac risk, use of strontium ranelate was not associated with any...
Autores principales: | Cooper, C., Fox, K. M., Borer, J. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer London
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906542/ https://www.ncbi.nlm.nih.gov/pubmed/24322476 http://dx.doi.org/10.1007/s00198-013-2582-4 |
Ejemplares similares
-
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
por: Cesareo, Roberto, et al.
Publicado: (2010) -
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
por: Reginster, J-Y., et al.
Publicado: (2011) -
Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis
por: Roux, C, et al.
Publicado: (2008) -
Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy
por: Blake, Glen M, et al.
Publicado: (2006) -
Efficacy of Strontium Ranelate in Combination with a D-Hormone Analog for the Treatment of Postmenopausal Osteoporosis
por: Abboskhujaeva, Lola S., et al.
Publicado: (2014)